StreetInsider.com News Articles

Form 8-K Vistagen Therapeutics, For: Sep 10

Fri, 11 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260911/27050356.html

Vistagen to Present at Psych Congress 2026

Thu, 10 Sep 2026 08:30:00 -0400

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18,

Vistagen to Present at Psych Congress 2026

Thu, 10 Sep 2026 08:30:00 -0400

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260814/26933045.html

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260814/26933045.html

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931471.html

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931471.html

Form 10-Q Vistagen Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930766.html

Form 10-Q Vistagen Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930766.html

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930183.html

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930183.html

Form 8-K Vistagen Therapeutics, For: Aug 14

Fri, 14 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26925285.html

Form 8-K Vistagen Therapeutics, For: Aug 14

Fri, 14 Aug 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26925285.html

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Fri, 14 Aug 2026 08:32:00 -0400

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder

Appointments of Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D. to the Board add decades of neuroscience drug development experience

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Fri, 14 Aug 2026 08:32:00 -0400

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder

Appointments of Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D. to the Board add decades of neuroscience drug development experience

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Fri, 14 Aug 2026 08:32:00 -0400

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder

Appointments of Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D. to the Board add decades of neuroscience drug development experience

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Fri, 14 Aug 2026 08:32:00 -0400

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder

Appointments of Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D. to the Board add decades of neuroscience drug development experience

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry

Form 8-K Vistagen Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884312.html

Form 8-K Vistagen Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884312.html

Vistagen reports Phase 2 repeat dose results for fasedienol in SAD

Thu, 06 Aug 2026 08:31:17 -0400

Vistagen (Nasdaq: VTGN) released topline results from an exploratory Phase 2 repeat dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder (SAD), according to a company statement.

The three-arm, multicenter, randomized, double-blind, placebo-controlled study enrolled 61 adult subjects and compared two sequential 3.2 µg doses of fasedienol administered ten minutes apart against a single 3.2 µg dose and placebo. The study was not designed to demonstrate statistically significant differences between treatment groups.

On the primary endpoint, mean change in subjective units of distress (SUDS) score, both active arms showed numerical separation from placebo but did not reach

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Thu, 06 Aug 2026 08:30:00 -0400

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose

Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement

Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Thu, 06 Aug 2026 08:30:00 -0400

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose

Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement

Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Thu, 06 Aug 2026 08:30:00 -0400

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose

Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement

Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Thu, 06 Aug 2026 08:30:00 -0400

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose

Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement

Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway

Form 8-K Vistagen Therapeutics, For: Aug 04

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873830.html